Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned an average rating of “Hold” from the eleven analysts that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $381.44.

A number of research analysts have recently issued reports on the company. TD Cowen decreased their target price on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Finally, Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Grant Private Wealth Management Inc purchased a new position in Medpace during the fourth quarter worth approximately $279,000. Trexquant Investment LP increased its stake in shares of Medpace by 130.6% in the 4th quarter. Trexquant Investment LP now owns 35,501 shares of the company’s stock worth $11,794,000 after acquiring an additional 20,103 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Medpace during the 4th quarter worth $1,057,000. Geode Capital Management LLC boosted its position in shares of Medpace by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company’s stock valued at $218,031,000 after acquiring an additional 28,076 shares during the last quarter. Finally, Nemes Rush Group LLC purchased a new stake in shares of Medpace in the fourth quarter valued at about $86,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of Medpace stock opened at $336.47 on Thursday. The firm has a 50-day simple moving average of $343.90 and a two-hundred day simple moving average of $348.96. Medpace has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The company has a market cap of $10.46 billion, a P/E ratio of 29.46, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. Equities research analysts forecast that Medpace will post 11.93 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.